Pay in 4 interest-free payments of $7.27 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Anstey KJ, Ee N, Eramudugolla R, Jagger C, Peters R
Further Reading All Addiction Content Tremors Following Alcohol Dependency Video Game Addiction Symptoms, Diagnosis and Treatment Sun Addiction: Evolutionary Survival Advantage
doi:10.2337/dc14-1850 46
Antibiotics : Ciprofloxacin and levofloxacin may interact with GLUTONE INJECTION 1, potentially affecting its antioxidant properties and the medicine's efficacy
Phase 3 data (TRIUMPH-4) showed average weight loss of 28.7% body weight at the 12mg dose over 68 weeks, equivalent to approximately 71.2 pounds from an average starting weight of 248.5 pounds
Receptor-target and efficacy comparison: GLP-1 class agents | Agent | GLP-1 | GIP | Glucagon | Approval | Best trial weight loss | |---|---|---|---|---|---| | Liraglutide (Saxenda) | Yes | No | No | FDA-approved | 8.0% at 56 weeks (SCALE) | | Dulaglutide (Trulicity) | Yes | No | No | T2D only | 3.0 kg mean at 52 weeks | | Semaglutide (Wegovy) | Yes | No | No | FDA-approved | 14.9% at 68 weeks (STEP-1) | | Tirzepatide (Zepbound) | Yes | Yes | No | FDA-approved | 20.9% at 72 weeks (SURMOUNT-1) | | Retatrutide | Yes | Yes | Yes | Investigational | 24.2% at 48 weeks (Phase 2) | Liraglutide and Dulaglutide: Where They Fit Now Liraglutide (Saxenda, 3 mg once daily subcutaneous) was the first GLP-1 agonist approved specifically for obesity in the United States
